Improving Access to Lifesaving Treatments for Bleeding Disorders in the Developing World
CSL Behring marks World Hemophilia Day by donating its bleeding disorders medicines to the World Federation of Hemophilia (WFH).
MONTREAL and KING OF PRUSSIA, Pa. — 10 April 2017
- CSL Behring Marks World Hemophilia Day by Donating IUs of its Bleeding Disorders Medicines to the World Federation of Hemophilia
- World Hemophilia Day 2017 Shines a Light on the Millions of Women and Girls Who Are Living with a Bleeding Disorder
The World Federation of Hemophilia (WFH) and global biotherapeutics leader CSL Behring announced today that CSL Behring has shipped more than 4 million international units (IUs) of its medicines to treat hemophilia A and/or von Willebrand Disease to the WFH Global Alliance for Progress (GAP) Program in recognition of World Hemophilia Day. The GAP Program strives to improve the diagnosis and treatment of bleeding disorders in developing countries. World Hemophilia Day, April 17, is promoted by WFH and supported by CSL Behring to increase global awareness of hemophilia and other inherited bleeding disorders.
“This year’s theme for World Hemophilia Day is ‘Hear Their Voices’,” said Alain Baumann, Chief Executive Officer, World Federation of Hemophilia. "There are millions of women and girls around the world living with a bleeding disorder and improving the diagnosis and access to care for the millions of people around the world who have a bleeding disorder and no access to treatment is one of our missions. CSL Behring supports this mission and we are grateful for our longstanding partnership.”
This donation of coagulation factor concentrates is a part of CSL Behring’s promise to provide 10 million IUs of one or more of its medicines for bleeding disorders to the WFH over three years (from 2016 to 2018). In 2009, CSL was the first biotechnology leader to provide coagulation factor donations in support of the WFH Humanitarian GAP Program in a multi-year agreement. Since then, CSL Behring has donated more than 20 million IUs of its bleeding disorder treatments to WFH for use in developing countries and made significant financial contributions to the organization.
“The GAP Program has helped improve the lives of people who are living with hemophilia around the world by improving treatment access in developing countries,” said Jens Oltrogge, Head of Commercial Development Coagulation, CSL Behring. “This World Hemophilia Day we are proud to continue to support the GAP Program’s mission. We are also pleased to partner with the bleeding disorders community to increase awareness and diagnosis of all patients living with a bleeding disorder.”
About the Global Alliance for Progress Program
The Global Alliance for Progress (GAP) Program is a healthcare development project launched in 2003, now in its second decade phase (2013-2022). The overarching goals for the GAP Program will be to increase by 50,000 the worldwide number of people identified/diagnosed with a bleeding disorder, as well as to ensure that 50 percent of those newly diagnosed are from the world’s most impoverished countries. CSL Behring supports the WFH GAP Program as one of the program sponsors.
About the World Federation of Hemophilia
For over 50 years, the World Federation of Hemophilia (WFH), an international not-for-profit organization, has worked to improve the lives of people with hemophilia and other inherited bleeding disorders. Established in 1963, it is a global network of patient organizations in 134 countries and has official recognition from the World Health Organization. Visit WFH online at www.wfh.org.
About CSL Behring
CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL), headquartered in Melbourne, Australia, employs nearly 20,000 people, delivering its life-saving therapies to people in more than 60 countries. For more information visit www.cslbehring.com and follow us on www.Twitter.com/CSLBehring.